Thursday, March 17, 2011

Cervical Fluid 19 Day

Sintrom 20CPR 4MG

Active acenocoumarol
Group Product Type
Antithrombotic therapy prescription drugs scheme SSN CONCEDIB.ESENTE
Class A Recipe Type RR - Repeat
Form Farm. TABLETS Container TUBE
Validity Date 60 MONTHS Commerce. Price
ATC B01AA07
The product contains no gluten, gluten
Manufacturer NOVARTIS FARMA SpA



Pharmacotherapeutic
oral anticoagulants.


INDICATIONS Treatment and prevention of thromboembolic diseases.

CONTRAINDICATIONS / EFF.SECONDAR
Hypersensitivity 'note all'acenocumarolo and coumarin derivatives runs
sides. Pregnancy. Lack of cooperation from the patient (p.es
. Patients are not subject to close surveillance, the elderly, alcoholics and patients with psychiatric disorders
). Sintrom and '
also contraindicated in all disease states in which the risk of bleeding and' Mag
greater clinical benefit as possible, for example, bleeding diathesis
and / or blood dyscrasia, and immediately before or after surgery on
central nervous system, as well as 'operations and ophthalmic interventions c
hirurgici massive, presence of peptic ulcer or bleeding in
to treat gastrointestinal, urogenital tract or the respiratory system
I, as well as' if cerebrovascular hemorrhage, pericarditis and pericardial versa
minds, and subacute bacterial endocarditis, severe hypertension or serious injury
parenchymal liver and kidney increased activity 'fi
brinolitica as after operations on the lungs, prostate, uterus, etc.
gr ave failure with circulatory stasis liver.

DOSAGE
GENERAL RULES. The sensitivity 'to anticoagulants varies from
patient to patient and can 'also fluctuate during the course of treatment. Therefore
and 'essential to carry out regular analysis of coagulation Idone
centers for standardized laboratory tests and can adapt
ology on the basis of results from this analysis. If this 'is not
' Sintrom can not be used. The dosage should always be newspapers
ra prescribed as a single dose, and always
ssunta the same time each day. To adjust the dosage to
different conditions are compared and the other paragraphs. Sintra
me 'available as tablets of 1 and 4 mg. For the recruitment of
the low doses we recommend using tablets of 1 mg and conse
ntoni greater accuracy of dosing. INITIAL DETERMINATION. When
thromboplastin time before treatment and 'go
within normal values, the recommended dosage and' generally as follows: FIRST DAY
: 8 (-12) mg; DAY TWO: 4 (-8) mg. If the time trombop
dip stick and 'initially abnormal, treatment should be started on c
extreme caution. Mantini THERAPY AND ANALYSIS OF ONE
coagulation. In view of the marked individual differences observed
maintenance dose must be determined on the basis of the results of laboratory analysis
to be carried out periodically to determine the temperature
bit of the patient's blood coagulation. An accurate adjustment of the maintenance dose
individual can 'only be obtained average
doors close monitoring of the Quick values \u200b\u200b(or INR) at intervals reg
Olarte, p. es. once a month, so as to avoid possible fluctuations in
ions (deviations interval therapy). Based on the value of
Quick (or INR), as well as' the individual patient and the nature of the illness on
, the maintenance dose is generally between 1 and 8 mg per day
. As a matter of routine measurement of time tromboplasti
na gives good results. Both before and after initiation of treatment
that, until the value of coagulation off within iv
alues \u200b\u200bbest, this must be examined daily in oral
pedal. The interval between examinations can 'then be extended. S
recommended that the blood samples are taken for laboratory analysis
laboratory at the same time each day. For purposes 'standardizzazion
ee' was introduced to the INR (International Normalised Ratio)
c h, with the help of calibrated thromboplastins allows a comp nt
International. The INR and 'the ratio of thromboplastin time
to the test plasma and normal, elevated to the power of s pecific
"International Sensitivity Index'," as determined by the
reference thromboplastin using the procedure of the WHO
. When the Quick value decreases, the thromboplastin time of
patient's blood increases, and so the INR becomes 'more' high. In b ase
the clinical picture, the therapeutic range is to be achieved against
is usually an INR between 2.0 and 4.5, within this
ntervallo the majority of patients do not manifest it 's a r
icomparsa of thrombosis, there 'any haemorrhagic
g rave. After discontinuation of treatment with Sintrom there and 'generates
lment no danger of hypercoagulability'
reactive and thus no need to gradually decrease the dosage
in case of interruption of treatment. However, and 'has been observed that in cases
extremely rare and in some patients at high risk (eg.
rdico after myocardial infarction) may' occur 'hypercoagulability' bounce '. In these institutions Pazi
discontinuation of anticoagulant therapy should be done gradually
mind.

INTERACTIONS
Of the many possible interactions between coumarin and other drugs
, refer only clinically relevant. The mechanisms set
rtanti involved in these interactions are: disorders of absorption,
inhibition or induction of metabolic enzyme system and have been reduced
to availability 'of vitamin K required to range? carbossilazi
one of the factors of the prothrombin complex. Although 'only a limited number
Committee of interactions are significant, each treatment can' lead
the risk of interactions. Hence the need 'to sorveglianz
attentive to and frequent tests of coagulation (eg twice a week
ana) when prescribing for the first time any drug co
mbinazione with Sintrom or if you suspend a drug
administered simultaneously. The anticoagulant effect can 'be enhanced c
on the following drugs: allopurinol, anabolic steroids, androgens
, antiarrhythmic agents (eg amiodarone, quinidine), antibiotics (p.es
. Erythromycin, neomycin, tetracycline, chloramphenicol), feniramidolo
, clofibrate derivatives and structurally similar, disulfiram, et
acrinico acid, glucagon, histamine H2 receptor antagonists, deriv ati
imidazoles (eg. metronidazole and, even when given the
cally, miconazole), sulfa drugs long term (including cotrimoxaz
oils), oral antidiabetics, thyroid hormones (including destrotirossina)
sulfinpyrazone, cimetidine, chloral hydrate, nalidixic acid. Durant
and treatment with drugs that affect homeostasis, the effect of an anticoagulation can
'and therefore can be enhanced' I
increase the risk of gastrointestinal bleeding. Among these drugs the most 'important are the
heparin as well as' the following inhibitors plate
inic: salicylic acid and its derivatives (eg, acetylsalicylic acid,
paraminosalicilico acid, diflunisal), phenylbutazone, or other derivatives
pyrazolone (sulfinpyrazone). The use of such halts
Sintrom associated with alliances and 'therefore highly recommended. When using in combination
tion with other NSAIDs, it is recommended
to make more frequent coagulation analysis. L '
anticoagulant effect can' decrease during treatment concurrent
nte with the following medications: aminoglutethimide, barbiturates, carbamazepi
na, cholestyramine, griseofulvin, oral contraceptives, card
ioattivi glycosides, corticosteroids, rifampicin and thiazide diuretics.
during treatment with hydantoin derivatives, can 'increase the serum concentration
one dell'idantoina. Cholestyramine reduces the absorption int
estinale, mainly to interruption of enterohepatic circulation;
why it can 'be recommended as a treatment of the s
ovradosaggio a coumarin derivative. During concomitant treatment
chin with sulphonylurea derivatives may 'increase the hypoglycemic effect of these drugs
icemizzante. Because 'it' gravity ', it' the first sint
omi interactions can be expected, the patients taking
It ntrom, especially if suffering from liver dysfunction, you should abstain from consuming
quantity 'rather high in alcohol. The radio
therapy or switching from conditions of immobilization in bed (for example
hospitalization), those of active mobilization (for
XAMPLE and discharge), or vice versa, and in patients in whom RA was already
'A balance regimen, often require u n
readjustment of dosage.

SIDE EFFECTS
depending on the intensity 'of therapy, age' of the patient and
na ture of the underlying disease (but not the duration of treatment), c
omplicazioni the most 'frequently reported with anticoagulants
have been bleeding in different parts of the body. If there ia
hemorrhage in a patient whose thromboplastin time is included in the re
therapeutic value, the case must be examined diagnostically (in view of the possibility
', eg, ulceration, tumors, congenital disorders of co
Agulo). The bleeding occurs mainly in the gastro
ointestinale (melena), in the brain, genitourinary tract (hematuria
macro and microscopic), uterus (metrorrhagia and menorrhagia) in FEGA
to and in the gallbladder (ematobilia), and eye. The crowds gastroint
estinali (Loss of appetite, nausea, vomiting) and allergic reactions
and in the form of urticaria, dermatitis and fever, as well as'
revers ible loss of hair (alopecia) have rarely been noted with similar coumarin derivatives
. Were also reported isolated cases of necrosis of the skin
bleeding, usually associated with congenital deficiency of pr
oteina C, and liver damage.

0 comments:

Post a Comment